The Technion’s story has been intertwined with Israel’s for more than a century, from laying the foundations for a new nation to shaping its future.
Step inside Israeli innovation at the David and Janet Polak Visitors Center. Experience our 360° immersive movie and tech exhibition. Open to individuals and groups.
Learn MoreAs Seen in Ynetnews.com
An innovative technology developed by researchers at the Technion – Israel Institute of Technology could lead to a fundamental shift in the cancer treatment paradigm. They created advanced nanoparticles that successfully halt aggressive triple-negative breast cancer tumors – without releasing a single drug molecule. The particles operate through a sophisticated interaction with the immune system, changing the rules of the game by delivering a biological message to the tumor microenvironment and to immune system cells.
Published in ACS Nano, the study was led by Ph.D. candidate Ofri Vizenblit, with the assistance of Ph.D. candidate Rawan Mhajne, under the supervision of Assistant Professor Assaf Zinger, head of the Bioinspired Nano Engineering and Translational Therapeutics Laboratory in the Wolfson Faculty of Chemical Engineering.
Triple-negative breast cancer is considered one of the most aggressive and difficult cancers to treat. It is characterized by rapid progression and high resistance to conventional therapies. The new paradigm change presented by Technion researchers is based on a revolutionary approach: instead of attacking the cancer cells themselves, it targets the environment in which they exist and develop.